HLB Acquires VERISMO Shares Worth 5.7 Billion KRW... 10% Stake
[Asia Economy Reporter Hyunseok Yoo] HL Biopharma, a KOSDAQ-listed company, announced on the 29th that it will acquire 1,912,777 shares of the biopharmaceutical development company VERISMO THERAPEUTICS for approximately 5.7 billion KRW.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- ‘Funds Depleted’ Homeplus Faces Shutdown Crisis at 67 Stores... Pleads with Meritz for Emergency Loan
- "Target Price Set at 970,000 Won"... Top Investors Already Watching, Only an 'Uptrend' Remains [Weekend Money]
After the acquisition, the shareholding ratio will be 10%. The scheduled acquisition date is the 12th of next month. HL Biopharma explained the purpose of the stock acquisition as "maximizing corporate value through equity acquisition."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
